Haddish-Berhane N - Search Results

1

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

Pfefferkorn JA, Guzman-Perez A, Litchfield J, Aiello R, Treadway JL, Pettersen J, Minich ML, Filipski KJ, Jones CS, Tu M, Aspnes G, Risley H, Bian J, Stevens BD, Bourassa P, D'Aquila T, Baker L, Barucci N, Robertson AS, Bourbonais F, Derksen DR, Macdougall M, Cabrera O, Chen J, Lapworth AL, Landro JA, Zavadoski WJ, Atkinson K, Haddish-Berhane N, Tan B, Yao L, Kosa RE, Varma MV, Feng B, Duignan DB, El-Kattan A, Murdande S, Liu S, Ammirati M, Knafels J, Dasilva-Jardine P, Sweet L, Liras S, Rolph TP. Pfefferkorn JA, et al. J Med Chem. 2012 Feb 9;55(3):1318-33. doi: 10.1021/jm2014887. Epub 2012 Jan 24. J Med Chem. 2012. PMID: 22196621

2

Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology.

Maurer TS, Ghosh A, Haddish-Berhane N, Sawant-Basak A, Boustany-Kari CM, She L, Leininger MT, Zhu T, Tugnait M, Yang X, Kimoto E, Mascitti V, Robinson RP. Maurer TS, et al. AAPS J. 2011 Dec;13(4):576-84. doi: 10.1208/s12248-011-9297-2. Epub 2011 Aug 26. AAPS J. 2011. PMID: 21870203 Free PMC article.

3

A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART^®.

Betts A, Haddish-Berhane N, Shah DK, van der Graaf PH, Barletta F, King L, Clark T, Kamperschroer C, Root A, Hooper A, Chen X. Betts A, et al. AAPS J. 2019 May 22;21(4):66. doi: 10.1208/s12248-019-0332-z. AAPS J. 2019. PMID: 31119428 Free PMC article.

4

Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.

Betts AM, Haddish-Berhane N, Tolsma J, Jasper P, King LE, Sun Y, Chakrapani S, Shor B, Boni J, Johnson TR. Betts AM, et al. AAPS J. 2016 Sep;18(5):1101-1116. doi: 10.1208/s12248-016-9929-7. Epub 2016 May 19. AAPS J. 2016. PMID: 27198897

5

Correction to: A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®.

Betts A, Haddish-Berhane N, Shah DK, van der Graaf PH, Barletta F, King L, Clark T, Kamperschroer C, Root A, Hooper A, Chen X. Betts A, et al. AAPS J. 2019 Jun 4;21(4):73. doi: 10.1208/s12248-019-0348-4. AAPS J. 2019. PMID: 31165304 Free PMC article.

6

Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin.

Shah DK, Haddish-Berhane N, Betts A. Shah DK, et al. J Pharmacokinet Pharmacodyn. 2012 Dec;39(6):643-59. doi: 10.1007/s10928-012-9276-y. Epub 2012 Nov 15. J Pharmacokinet Pharmacodyn. 2012. PMID: 23151991

7

Mechanistic Projection of First-in-Human Dose for Bispecific Immunomodulatory P-Cadherin LP-DART: An Integrated PK/PD Modeling Approach.

Chen X, Haddish-Berhane N, Moore P, Clark T, Yang Y, Li H, Xuan D, Barton HA, Betts AM, Barletta F. Chen X, et al. Clin Pharmacol Ther. 2016 Sep;100(3):232-41. doi: 10.1002/cpt.393. Epub 2016 Jul 21. Clin Pharmacol Ther. 2016. PMID: 27170541

8

On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.

Haddish-Berhane N, Shah DK, Ma D, Leal M, Gerber HP, Sapra P, Barton HA, Betts AM. Haddish-Berhane N, et al. J Pharmacokinet Pharmacodyn. 2013 Oct;40(5):557-71. doi: 10.1007/s10928-013-9329-x. Epub 2013 Aug 10. J Pharmacokinet Pharmacodyn. 2013. PMID: 23933716

9

SIMDOT-AbMe: microphysiologically based simulation tool for quantitative prediction of systemic and local bioavailability of targeted oral delivery formulations.

Haddish-Berhane N, Farhadi A, Nyquist C, Haghighi K, Keshavarzian A. Haddish-Berhane N, et al. Drug Metab Dispos. 2009 Mar;37(3):608-18. doi: 10.1124/dmd.108.021949. Epub 2008 Dec 1. Drug Metab Dispos. 2009. PMID: 19047471

10

Establishing in vitro-in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach.

Shah DK, Loganzo F, Haddish-Berhane N, Musto S, Wald HS, Barletta F, Lucas J, Clark T, Hansel S, Betts A. Shah DK, et al. J Pharmacokinet Pharmacodyn. 2018 Apr;45(2):339-349. doi: 10.1007/s10928-018-9577-x. Epub 2018 Feb 8. J Pharmacokinet Pharmacodyn. 2018. PMID: 29423862

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters